Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $47.88 USD
Change Today 0.00 / 0.00%
Volume 339.3K
TTPH On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

tetraphase pharmaceuticals i (TTPH) Snapshot

Open
$47.94
Previous Close
$47.88
Day High
$49.00
Day Low
$46.42
52 Week High
07/2/15 - $49.00
52 Week Low
07/17/14 - $10.03
Market Cap
1.7B
Average Volume 10 Days
653.7K
EPS TTM
$-2.61
Shares Outstanding
36.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TETRAPHASE PHARMACEUTICALS I (TTPH)

tetraphase pharmaceuticals i (TTPH) Related Bloomberg News

View More Bloomberg News

tetraphase pharmaceuticals i (TTPH) Related Businessweek News

No Related Businessweek News Found

tetraphase pharmaceuticals i (TTPH) Details

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. Its lead product candidate includes eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The company is conducting a Phase 3 clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and a second Phase 3 clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy. It is also developing TP-271, a preclinical compound for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a preclinical Gram-negative program for multidrug-resistant Gram-negative infections. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

55 Employees
Last Reported Date: 03/6/15
Founded in 2006

tetraphase pharmaceuticals i (TTPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $420.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $318.0K
Chief Operating Officer
Total Annual Compensation: $311.2K
Chief Medical Officer
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2014.

tetraphase pharmaceuticals i (TTPH) Key Developments

Tetraphase Pharmaceuticals, Inc. Presents at BIO International Convention 2015, Jun-18-2015 11:15 AM

Tetraphase Pharmaceuticals, Inc. Presents at BIO International Convention 2015, Jun-18-2015 11:15 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: John Craig Thompson, Chief Operating Officer.

Tetraphase Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 03:00 PM

Tetraphase Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 03:00 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Guy MacDonald, Chief Executive Officer, President and Director.

Tetraphase Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Tetraphase Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $20,760,000, net loss of $20,986,000 or $0.66 loss per share basic and diluted on revenues of $3,016,000 against loss from operations of $13,218,000, net loss of $13,523,000 or $0.53 loss per share on revenues of $2,457,000 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TTPH:US $47.88 USD 0.00

TTPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TTPH.
View Industry Companies
 

Industry Analysis

TTPH

Industry Average

Valuation TTPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 157.4x
Price/Book 6.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 152.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TETRAPHASE PHARMACEUTICALS I, please visit www.tphase.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.